Translational Regulation of T Regulatory Cells

调节性 T 细胞的翻译调控

• 批准号: 10356140
• 负责人: Robert Schneider
• 金额: $ 60.64万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-03-01 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10356140
• 关键词: 5' Untranslated Regions; Animal Model; Applications Grants; Autoimmune Diseases; Binding Proteins; Biological Process; Cell Differentiation process; Consensus; Consensus Sequence; Development; Elements; Exposure to; Generations; Genetic Translation; Goals; Human; Immunocompetent; Immunosuppression; Immunosuppressive Agents; Immunotherapy; Malignant Neoplasms; Messenger RNA; Modeling; Molecular; Proteins; Regulation; Regulatory T-Lymphocyte; Research; Role; Testing; Transforming Growth Factor beta; Translational Regulation; Translations; Work; base; immune activation; immunoregulation; insight; mTOR inhibition; therapeutically effective; tumor

Project Summary The goal of this work is to develop a fundamental understanding of the translational regulation of T regulatory cell (Treg) development, of which very little is known, which can inform the development of more effective therapeutic approaches to the regulation of Tregs in human cancer and autoimmune disease. Our research has provided important insights into the molecular regulation of selective mRNA translation in Treg development which we ultimately seek to capitalize on in generation of more effective immune-based therapies. This work is directed to understanding and then targeting the privileged translation of Treg fate determining mRNAs. The objective of our research is to determine the mechanism at the level of translational control which key Treg mRNAs promote Treg development and immune suppression functions.

项目摘要 这项工作的目标是发展一个基本的理解的翻译调控的T调节 细胞（Treg）的发展，其中知之甚少，这可以告知更有效的发展 在人类癌症和自身免疫性疾病中调节TcR的治疗方法。我们的研究 为Treg中选择性mRNA翻译的分子调控提供了重要的见解 我们最终寻求利用这些发展来产生更有效的基于免疫的 治疗这项工作是针对理解，然后针对特权翻译的Treg命运 确定mRNA。我们的研究目的是确定翻译水平上的机制 控制哪些关键Treg mRNA促进Treg发育和免疫抑制功能。